Study S002326

Do Appetitive Gut Hormones Reduce Addictive and Eating Behaviours in Obesity, and Nicotine and Alcohol Dependence?

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02690987
Acronym: GHADD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: EARLY_PHASE1
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 95
Start: 2015-08
Primary completion: 2019-08-21
Lead sponsor: Imperial College London
Conditions: Obesity; Smoking Cessation; Alcoholism
Interventions: DRUG:Exenatide; BIOLOGICAL:Desacyl ghrelin; BIOLOGICAL:Saline
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER_GRANT:MR/M007022/1

Registered primary outcomes

Functional MRI measure of brain activation during cigarette, alcohol and food picture evaluation task [4 years]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020061	GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. van Bloemendaal L, Diabetes	2014	Randomized trial	PMID 25071023 DOI	registry reference BACKGROUND:25071023
R0016561	The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. Egecioglu E, PloS one	2013	Preclinical	PMID 24204788 DOI	registry reference BACKGROUND:24204788
R0021159	Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. Shirazi RH, PloS one	2013	Preclinical	PMID 23613987 DOI	registry reference BACKGROUND:23613987